Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Oxford BioMedica's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:OXB vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Oxford BioMedica's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica (LSE:OXB) has a FCF Margin % of -6.67% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Oxford BioMedica and its competitors. According to the industry distribution chart, Oxford BioMedica ranks #257 out of 954 companies in the Biotechnology industry, placing it in the top 26.9%.
Is Oxford BioMedica's FCF Margin % too high?
Oxford BioMedica's current FCF Margin % is -6.67%. Based on the distribution chart, Oxford BioMedica ranks #257 out of 954 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oxford BioMedica has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #257 out of 954 companies for FCF Margin %. This puts Oxford BioMedica in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Oxford BioMedica and its competitors. Oxford BioMedica's current FCF Margin % is -6.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (LSE:OXB) is currently considered Fairly Valued. The stock's GF Value™ is £5.46, compared to a current price of £5.05 — trading 7.5% below its estimated fair value. The current FCF Margin % is -6.67%. Oxford BioMedica's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Oxford BioMedica (LSE:OXB), the current FCF Margin % is -6.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be undervalued.
The current stock price of £5.05 is trading 7.5% below its estimated GF Value™ of £5.46.
GuruFocus considers Oxford BioMedica to be Fairly Valued.
Key valuation signals for LSE:OXB:
FCF Margin %: -6.67%
GF Value™: £5.46 vs. price of £5.05 (7.5% below fair value)
No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
69GF Score
Get the complete analysis for LSE:OXB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:OXB has been successfully added to your 
